Back to Blog

If you have eczema — atopic dermatitis — you likely dread the arrival of Michigan winters. The cold, dry air outdoors; the forced-air heat indoors; the long, hot showers that feel necessary but inevitably backfire. Winter creates a near-perfect storm for eczema flares, and patients who are well-controlled in summer often find themselves scrambling for relief by January. Here's what's happening biologically, and what evidence-based strategies actually work.

Why Winter Makes Eczema Worse

Atopic dermatitis is fundamentally a skin barrier disorder. People with eczema have defects — often genetic — in filaggrin, a protein critical to maintaining the outermost protective layer of skin (the stratum corneum). This results in a leaky, compromised barrier that loses water more easily and allows environmental irritants and allergens to penetrate. In winter, several factors compound this vulnerability:

Understanding the Itch-Scratch Cycle

Eczema isn't just dry skin — it's a chronic inflammatory condition driven by Th2-skewed immune responses, with interleukins IL-4 and IL-13 playing central roles in disease pathogenesis. This inflammation generates itch, scratching damages the barrier further, which allows more allergen penetration and more inflammation. Breaking this cycle — not just moisturizing over it — is the goal of modern eczema management.

Important distinction: "Dry skin" (xerosis) and atopic dermatitis are not the same condition. Many people have both, but eczema involves immune dysregulation that requires targeted treatment beyond moisturizer alone. If your "dry skin" doesn't respond to aggressive moisturization, has appeared since childhood, comes with a personal or family history of asthma or allergies, or involves intense itch — see a dermatologist.

The Science of Moisturizers: Which Type You Actually Need

Not all moisturizers work the same way. Understanding the three functional categories helps you choose what your skin genuinely needs in winter:

Type 1

Humectants

Attract water from the deeper layers of skin and from the environment (when humidity is adequate). Draw moisture toward the skin surface.

Examples: glycerin, hyaluronic acid, urea (at low concentrations), lactic acid

Type 2

Emollients

Fill gaps between skin cells, smoothing and softening the surface. Reinforce the lipid matrix of the stratum corneum.

Examples: ceramides, fatty acids, squalane, shea butter, dimethicone

Type 3

Occlusives

Form a physical barrier on the skin surface to prevent water loss. Most powerful water-retaining category — essential in winter.

Examples: petrolatum (Vaseline), lanolin, mineral oil, beeswax

For winter eczema management, the most effective moisturizers combine all three categories. Petrolatum alone (plain Vaseline) is one of the most evidence-backed options for severe dryness and eczema — inexpensive, fragrance-free, and more effective at reducing TEWL than most branded "eczema creams." Medical-grade ceramide-containing creams (CeraVe Moisturizing Cream, Vanicream) are excellent alternatives with better cosmetic elegance.

The "Soak and Seal" Method

A cornerstone of eczema management during flares, soak and seal dramatically improves barrier function and medication penetration:

Practical Winter Trigger Management

Treatment Options: From Mild to Severe

Moisturization is foundational, but most patients with moderate-to-severe eczema need additional medical treatment during winter flares. Options are more numerous and more effective than ever:

Mild–Moderate

Topical Corticosteroids

First-line treatment for most flares. Strength is matched to location (low-potency for face and skin folds; mid-to-high for body). Use only during active flares to avoid atrophy with chronic use.

Mild–Moderate

Topical Calcineurin Inhibitors

Tacrolimus (Protopic) and pimecrolimus (Elidel) are steroid-free options ideal for sensitive areas (face, eyelids, skin folds). No risk of skin thinning; can be used long-term.

Moderate–Severe

Crisaborole (Eucrisa)

A nonsteroidal PDE-4 inhibitor ointment. Anti-inflammatory without steroid side effects. Approved for mild-to-moderate atopic dermatitis in patients 2 years and older.

Moderate–Severe

Dupilumab (Dupixent)

A biologic injection (every 2 weeks) that blocks IL-4 and IL-13 receptors — the central drivers of atopic inflammation. A transformative option for moderate-to-severe eczema; often achieves near-complete clearance.

Moderate–Severe

JAK Inhibitors

Oral agents (upadacitinib/Rinvoq, abrocitinib/Cibinqo) and topical ruxolitinib (Opzelura) target JAK signaling pathways downstream of itch and inflammation. Rapid onset of action, often within days.

Acute Flares

Short-course Oral Corticosteroids

Prednisone provides rapid relief during severe flares but is not appropriate for chronic management. Rebound flares are common; reserved as a bridge to longer-term therapy.

A Note on Biologics: A New Era for Eczema

For patients with moderate-to-severe eczema who haven't responded adequately to topicals, dupilumab (Dupixent) has genuinely changed lives. As the first biologic approved for atopic dermatitis (2017), it targets the Th2 inflammatory pathway with remarkable precision. Multiple clinical trials demonstrate 50–70% of patients achieving at least 75% improvement in disease severity (EASI-75). Unlike systemic immunosuppressants used previously (cyclosporine, methotrexate), dupilumab does not require routine blood monitoring and has a favorable long-term safety profile. If you've struggled with persistent, severe eczema, a dermatology consultation to discuss whether a biologic is appropriate for you is worth having.

Struggling with Winter Eczema Flares?

Dr. Qiblawi takes a comprehensive approach to eczema management — from trigger identification and barrier repair to the latest biologic therapies. Don't spend another Michigan winter miserable. Schedule a consultation at Summit Dermatology in Southgate.

Contact Us
Medical Disclaimer: This article is for educational purposes only and does not constitute personalized medical advice. Eczema treatment should be individualized in consultation with a board-certified dermatologist. References: Wollenberg A et al., European guidelines for atopic eczema, JEADV (2022); Eichenfield LF et al., AAD Guidelines for Atopic Dermatitis, JAAD (2014); Simpson EL et al. (SOLO Trials), NEJM (2016); National Eczema Association clinical resources.